Open Access Open Access  Restricted Access Subscription Access

To Study the Effect of Intravenous Tranexamic Acid on Blood Loss During and After Caesarean Section


Affiliations
1 Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Nashik - 422003, Maharashtra, India
 

Introduction: Incidence of postpartum haemorrhage is 6.4% in caesarean section. WHO guidelines for prevention of PPH include oxytocin as first line drug. Intravenous tranexamic acid has been used to reduce hemorrhage during surgical procedures. In this study use of tranexamic acid on blood loss during and after Lower Segment Caesarean Section (LSCS) was evaluated. Aims and Objectives: 1. To study the efficacy of tranexamic acid in reducing blood loss during and after lower segment caesarean section, and 2. To study any side effect on neonate. Materials and Methods: A randomized prospective observational study of 100 patients were conducted. Patients were divided into: Group (A group) had received 1 gm tranexamic acid intravenous 20 minutes before skin incision + 20 units oxytocin drip in 500ml Ringer Lactate after delivery of baby. Group (B group) received only 20 units oxytocin drip in 500ml Ringer Lactate after delivery of baby. Patient’s blood loss was measured (intra operative, post placental and post-operative period) by weighing dry and soaked mops and separate suction bottle for blood. Results: Statistically significant difference (P < 0.001) in the quantity of blood loss was observed. In group A total blood loss during LSCS was 476.49 ml while in group B it was 576.06 ml. Intra operative blood loss in group A was 455.63 ml while in group B it was 536.53 ml. Post placental blood loss in group A was 411.59 ml while in group B was 485.08 ml. Not a single neonate had poor APGAR score and no NICU admission was required. Conclusion: Use of tranexamic acid with oxytocin significantly decreased blood loss during and after caesarean section without any side effect on neonate.

Keywords

Lower Segment Caesarean Section (LSCS), Oxytocin, Post-Partum Haemorrhage, Tranexamic Acid.
Font Size

User
Notifications

  • Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC. Postpartum hemorrhage after caesarean delivery: An analysis of risk factors, South Med. J. 2005; 98:681-685. https://doi.org/10.1097/01.SMJ.0000163309.53317.B8, https://doi.org/10.1097/01.SMJ.0000152760.34443.86.
  • Who statement on caesarean section rates. Geneva: World health organization, 2015 (WHO/RHR/15.02).
  • World Health Organization. The Prevention and Management of Postpartum Haemorrhage. Report of a Technical Working Group, Geneva, 3-6 July, 1989. Unpublished document. WHO/MCH/90.7. Geneva: World Health Organization 1990.
  • Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid, Biochimicaet Biophysica Acta (BBA)-General Subjects. 1981; 673:75-85. https://doi.org/10.1016/0304-4165(81)90312-3.
  • Satyavathi K, Vemu NJ, Mohammed S. Tranexamic acid: A proven antifibrinolytic agent (A review), Oriental Journal of Chemistry. 2009; 25(4):987-992.
  • Pfanner G, Kilgert K. Hemorrhagic complications in obstetrics, Hamostaseologie. 2006; 26(3 Suppl 1):S56-63. [Article in German]. https://doi.org/10.1055/s-0037-1617083.
  • Levy JH, Dutton RP, Hemphill JC, Shander A, Cooper D, Paidas MJ, et al. Hemostasis summit participants: Multidisciplinary approach to the challenge of hemostasis, Anesth Analg. 2010; 110:354-364. https://doi.org/10.1213/ANE.0b013e3181c84ba5. PMid: 20007735.
  • Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, McClelland B, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion, Cochrane Database Syst. Rev. 2007; 4:CD001886. https://doi.org/10.1002/14651858.CD001886.pub2.
  • CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH2): A randomised, placebo controlled trial, Lancet. 2010; 376:23-32. https://doi.org/10.1016/S0140-6736(10)6083-55.
  • Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: A multi-center, randomized trial, Eur J. Obstet. Gynecol. Reprod. Biol. 2004 Feb 10; 112(2):154-157. https://doi.org/10.1016/S0301-2115(03)00287-2.
  • Gohel Mayur, Patel Purvi, Gupta Ashoo, Desai Pankaj. Efficacy of tranexamic acid in decreasing blood loss during and after caesarean section: A randomized case controlled prospective study, The J. of Obstet. Gynecol. of India. May/ June 2007; 57(3):227-230
  • Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti AD. Efficacy of tranexamic acid in reducing blood loss after caesarean section, Matern Fetal Neonatal Med. 2009 Jan; 22(1):9-5. https://doi.org/10.1080/14767050802353580. PMid: 19165682.

Abstract Views: 4

PDF Views: 0




  • To Study the Effect of Intravenous Tranexamic Acid on Blood Loss During and After Caesarean Section

Abstract Views: 4  |  PDF Views: 0

Authors

Monika Ganpat Thavare
Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Nashik - 422003, Maharashtra, India
Ajit Subhash Patil
Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Nashik - 422003, Maharashtra, India

Abstract


Introduction: Incidence of postpartum haemorrhage is 6.4% in caesarean section. WHO guidelines for prevention of PPH include oxytocin as first line drug. Intravenous tranexamic acid has been used to reduce hemorrhage during surgical procedures. In this study use of tranexamic acid on blood loss during and after Lower Segment Caesarean Section (LSCS) was evaluated. Aims and Objectives: 1. To study the efficacy of tranexamic acid in reducing blood loss during and after lower segment caesarean section, and 2. To study any side effect on neonate. Materials and Methods: A randomized prospective observational study of 100 patients were conducted. Patients were divided into: Group (A group) had received 1 gm tranexamic acid intravenous 20 minutes before skin incision + 20 units oxytocin drip in 500ml Ringer Lactate after delivery of baby. Group (B group) received only 20 units oxytocin drip in 500ml Ringer Lactate after delivery of baby. Patient’s blood loss was measured (intra operative, post placental and post-operative period) by weighing dry and soaked mops and separate suction bottle for blood. Results: Statistically significant difference (P < 0.001) in the quantity of blood loss was observed. In group A total blood loss during LSCS was 476.49 ml while in group B it was 576.06 ml. Intra operative blood loss in group A was 455.63 ml while in group B it was 536.53 ml. Post placental blood loss in group A was 411.59 ml while in group B was 485.08 ml. Not a single neonate had poor APGAR score and no NICU admission was required. Conclusion: Use of tranexamic acid with oxytocin significantly decreased blood loss during and after caesarean section without any side effect on neonate.

Keywords


Lower Segment Caesarean Section (LSCS), Oxytocin, Post-Partum Haemorrhage, Tranexamic Acid.

References





DOI: https://doi.org/10.18311/mvpjms%2F2019%2Fv6i1%2F18670